Principia Biopharmafounded In 2008 And Acquired By Sanofi In 2020Was A Clinical Stage Biopharmaceutical Company Based In South San Franciscocaliforniathe Company Focused On Developing Oral Small Molecule Therapies For Autoimmune Disorders And Oncologyit Utilized Its Proprietary Tailored Covalency Platform To Create Reversible Covalent Inhibitorsallowing For Precise Targeting Of Disease Pathways The Company S Key Products Included Rilzabrutiniba Btk Inhibitor For Conditions Like Pemphigus Vulgaris And Immune Thrombocytopeniaand Prn2246A Btk Inhibitor Designed To Cross The Blood Brain Barrier For Multiple Sclerosisother Pipeline Candidates Included Prn1371An Fgfr Inhibitor For Solid Tumorsand An Immunoproteasome Inhibitor For Inflammation And Autoimmune Disordersfollowing Its Acquisitionprincipia S Pipeline Has Been Integrated Into Sanofi S Immunology Portfoliowith Ongoing Trials For Various Indications
No conferences found for this company.
| Company Name | Principia Biopharma Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
